Targeted proteomics identification of biomarkers for diabetes mellitus in patients with cardiovascular disease

Doulamis, Ilias P.; Tzani, Aspasia; Konstantopoulos, Panagiotis; Antoranz, Asier; Plakia, Vaia; Minia, Angeliki; Gkogkos, Anastasios; Samanidis, George; Alexopoulos, Leonidas G.; Perrea, Despina

doi:10.1016/j.atherosclerosis.2017.06.847

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fang et al confirmed that elbasvir and ritonavir can significantly inhibit CSF3 protein expression [80], indicating that CSF3 is a potential target for the treatment of COVID-19. However, only a few studies have linked CSF3 to NAFLD progression [81].…”

Section: Discussionmentioning

confidence: 99%

Systems biology approach reveals a common molecular basis for COVID-19 and non-alcoholic fatty liver disease (NAFLD)

et al. 2022

View full text Add to dashboard Cite

Background Patients with non-alcoholic fatty liver disease (NAFLD) may be more susceptible to coronavirus disease 2019 (COVID-19) and even more likely to suffer from severe COVID-19. Whether there is a common molecular pathological basis for COVID-19 and NAFLD remains to be identified. The present study aimed to elucidate the transcriptional alterations shared by COVID-19 and NAFLD and to identify potential compounds targeting both diseases. Methods Differentially expressed genes (DEGs) for COVID-19 and NAFLD were extracted from the GSE147507 and GSE89632 datasets, and common DEGs were identified using the Venn diagram. Subsequently, we constructed a protein–protein interaction (PPI) network based on the common DEGs and extracted hub genes. Then, we performed gene ontology (GO) and pathway analysis of common DEGs. In addition, transcription factors (TFs) and miRNAs regulatory networks were constructed, and drug candidates were identified. Results We identified a total of 62 common DEGs for COVID-19 and NAFLD. The 10 hub genes extracted based on the PPI network were IL6, IL1B, PTGS2, JUN, FOS, ATF3, SOCS3, CSF3, NFKB2, and HBEGF. In addition, we also constructed TFs–DEGs, miRNAs–DEGs, and protein–drug interaction networks, demonstrating the complex regulatory relationships of common DEGs. Conclusion We successfully extracted 10 hub genes that could be used as novel therapeutic targets for COVID-19 and NAFLD. In addition, based on common DEGs, we propose some potential drugs that may benefit patients with COVID-19 and NAFLD.

show abstract

Section: Discussionmentioning

confidence: 99%